Abstract:
Stanozolol shows promise as an anabolic and anti-catabolic agent for treating degenerative joint disease (DJD). This study assessed the clinical efficacy of a single intra-articular stanozolol injection in canine knees with DJD and its correlation with serum IL-1β levels. Thirty dogs (n = 30) were divided into a control group (CG, n = 10) and a study group (SG, n = 20) with DJD. Pain levels were assessed using the Brown query, and radiographs were taken at T0 and T3. IL-1β levels were quantified via ELISA. Apart from 2 patients, all showed reduced pain intensity, with 15 patients showing improvement at T1 and 3 patients at T2. A positive correlation (r = 0.84; p < 0.01) was found between pain level and IL-1β in 15 patients. No systemic effects were observed. Most patients (18/20) experienced reduced pain. This pilot study suggests stanozolol\'s potential in managing DJD in dogs. Further research is warranted to validate these findings and understand stanozolol\'s mechanism in DJD treatment.
摘要:
Stanozolol显示出有望作为治疗退行性关节病(DJD)的合成代谢和抗分解代谢剂。本研究评估了单一关节腔内注射司坦唑醇在DJD犬膝关节中的临床疗效及其与血清IL-1β水平的相关性。30只狗(n=30)分为对照组(CG,n=10)和一个研究组(SG,n=20)与DJD。使用布朗查询评估疼痛水平,在T0和T3拍摄X线照片。通过ELISA定量IL-1β水平。除了2名患者,都显示疼痛强度降低,15名患者在T1和3名患者在T2时显示改善。15例患者的疼痛水平与IL-1β呈正相关(r=0.84;p<0.01)。没有观察到全身效应。大多数患者(18/20)经历疼痛减轻。这项初步研究表明,司坦唑醇在管理狗的DJD方面具有潜力。需要进一步的研究来验证这些发现并了解司坦唑醇在DJD治疗中的作用机制。